PTPRD antisense RNA 1 (PTPRD-AS1)

PTPRD antisense RNA 1 (PTPRD-AS1) is annotated as a long non-coding RNA (lncRNA) transcribed from the region opposite to the coding strand of the PTPRD (protein tyrosine phosphatase receptor type delta) gene[5]. Antisense RNAs such as PTPRD-AS1 typically regulate their sense gene counterparts at the transcriptional or post-transcriptional level, potentially influencing gene expression, splicing, or translation, but there are no current reports explicitly describing the function, molecular interactions, or disease relevance of PTPRD-AS1. The bulk of research and therapeutic interest centers on the protein-coding PTPRD gene itself, not its antisense RNA transcript[5][1][3][6]. - As a non-coding RNA, PTPRD-AS1 is not a typical drug target (such as a receptor, enzyme, or transporter) and may represent a genomic annotation rather than a functionally validated molecular target for therapy. - No drugs or experimental agents are reported to interact with PTPRD-AS1, and there are no published mechanisms of action or safety concerns. - No evidence links PTPRD-AS1 specifically to human disease or employs it as a biomarker, in contrast to the well-studied PTPRD protein which has established roles in cancer, neurological, and metabolic disorders[5][3][6]. Critical note: - The search results and current literature focus on the protein-coding PTPRD gene and receptor, not its antisense lncRNA. The target "PTPRD-AS1" as described is not a validated therapeutic target and should not be confused with the receptor-type protein tyrosine phosphatase delta (PTPRD). - If a therapeutic or research context specifies PTPRD-AS1 as a valid target, additional supporting functional evidence will be required, but as of now, it does not meet criteria for inclusion as a canonical therapeutic target[5].

Other names

PTPRD-AS1

Not applicable (no drugs reported to act on this target)